{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=22", "query": { "intervention": "Sequential Therapy", "page": 22 }, "page_size": 10 }, "pagination": { "page": 22, "page_size": 10, "total_count": 716, "total_pages": 72, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=23&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Sequential+Therapy&page=21&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T21:11:44.062Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00899977", "title": "TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Refractory Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TC-5214", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Targacept Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 1, "start_date": "2009-05", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-09-13", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899977" }, { "nct_id": "NCT00612313", "title": "Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression" ], "interventions": [ { "name": "Fluoxetine", "type": "DRUG" }, { "name": "Relapse prevention cognitive behavioral therapy (CBT)", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 144, "start_date": "2008-02", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2016-01-07", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612313" }, { "nct_id": "NCT02703623", "title": "Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma", "PSA Progression", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Apalutamide", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 196, "start_date": "2016-05-18", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 3, "location_summary": "Houston, Texas • Sugar Land, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02703623" }, { "nct_id": "NCT04396717", "title": "Safety Study of Pritumumab in Brain Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Primary Brain Tumors", "Brain Metastases, Adult" ], "interventions": [ { "name": "Pritumumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nascent Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2021-02-22", "completion_date": "2023-01-06", "has_results": false, "last_update_posted_date": "2024-12-06", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 2, "location_summary": "Newport Beach, California • San Diego, California", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04396717" }, { "nct_id": "NCT01528774", "title": "Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Blood Draw", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wolfram Samlowski", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2016-06", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-07-26", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT01528774" }, { "nct_id": "NCT04649385", "title": "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BGB-15025", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 157, "start_date": "2021-03-04", "completion_date": "2026-05-15", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 3, "location_summary": "New York, New York • Houston, Texas • San Antonio, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04649385" }, { "nct_id": "NCT00978432", "title": "Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-cell Lymphoma" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "LBH589", "type": "DRUG" }, { "name": "Doublet (RAD001 and LBH589)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anne Beaven, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2012-02", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-11-25", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00978432" }, { "nct_id": "NCT02047214", "title": "Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "TPI 287", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cortice Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2014-01", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02047214" }, { "nct_id": "NCT02275065", "title": "Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Bictegravir (GS-9883) in Human Immunodeficiency Virus (HIV)-1 Infected Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Bictegravir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2014-10-24", "completion_date": "2015-01-29", "has_results": true, "last_update_posted_date": "2020-11-09", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 16, "location_summary": "Berkeley, California • Davis, California • Long Beach, California + 13 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Davis", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02275065" }, { "nct_id": "NCT00975000", "title": "Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Allograft Nephropathy", "Chronic Kidney Disease", "Chronic Renal Failure", "Disordered Mineral Metabolism", "End Stage Renal Disease", "Hyperparathyroidism", "Hypophosphatemia", "Kidney Disease", "Kidney Transplantation", "Post Renal Transplantation" ], "interventions": [ { "name": "Cinacalcet", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2009-12-03", "completion_date": "2013-04-16", "has_results": true, "last_update_posted_date": "2018-10-17", "last_synced_at": "2026-10-29T21:11:44.062Z", "location_count": 15, "location_summary": "Phoenix, Arizona • Tempe, Arizona • San Francisco, California + 12 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975000" } ] }